Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its second quarter 2024 financial results and corporate update for Thursday, August 1, 2024. The schedule for the press release and conference call/webcast are as follows:
2024年7月18日,美國賓夕法尼亞州沃明斯特(WARMINSTER, Pa.)—世界生物製藥公司(納斯達克:ABUS),一家利用其豐富的病毒學專業知識開發治療慢性乙型肝炎病毒(cHBV)感染的功能性治療藥物的臨床前藥物實驗公司,今天宣佈計劃於2024年8月1日星期四公佈2024年二季度財務業績和公司更新。發佈和電話/網絡會議的時間表如下:
•Q2 2024 Press Release: | Thursday, August 1, 2024 at 7:30 a.m. ET | |
•Q2 2024 Conference Call/Webcast: | Thursday, August 1, 2024 at 8:45 a.m. ET |
•2024年第二季度新聞稿: | 2024年8月1日星期四 美國東部時間上午7:30 | |
•2024年第二季度電話/網絡會議: | 2024年8月1日星期四 美國東部時間上午8:45 |
To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at .
如需撥打電話參加電話會議,請使用以下鏈接進行註冊:Registration Link。會議的實時網絡廣播可以通過Arbutus公司的投資者網站訪問。
An archived webcast will be available on the Arbutus website after the event.
在大會之後,存檔的網絡廣播將在世界生物製藥公司的網站上提供。
About Arbutus
關於越桔公司
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in three Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit .
納斯達克:ABUS的臨床前製藥公司—世界生物製藥公司,利用其豐富的病毒學專業知識,確定開發具有不同作用機理的新型治療方案,用於治療慢性乙型肝炎病毒(cHBV)患者的功能性治療。我們認爲,成功開發功能性治癒的關鍵在於抑制乙肝病毒DNA,減少表面抗原,並提高乙肝特異性免疫反應。我們內部開發的專有化合物管線包括RNAi治療物Imdusiran(Ab-729)和口服PD-L1抑制劑Ab-101。Imdusiran產生了有意義的臨床數據,證明其對錶面抗原的減少和乙肝特異性免疫反應的再覺醒產生了影響。Imdusiran目前在三個2a期的臨床聯合試驗中進行。Ab-101正在進行1a/10億期的評估。有關更多信息,請訪問。
Contact Information
聯繫信息
Investors and Media
投資者和媒體
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
Lisa M. Caperelli
投資者關係副總裁
電話:215-206-1822
電子郵件:lcaperelli@arbutusbio.com